微流控技术在类器官药物筛选中的应用与发展趋势

doi:10.3981/j.issn.2097-0781.2024.03.007

前瞻科技 ›› 2024, Vol. 3 ›› Issue (3): 87-96.DOI: 10.3981/j.issn.2097-0781.2024.03.007

微流控技术在类器官药物筛选中的应用与发展趋势

潘建章¹^,²(), 郑欣雨¹, 方群¹^,²^,^†()

1.浙江大学化学系，微分析系统研究所，杭州 310058
2.浙江大学杭州国际科创中心，杭州 311200

收稿日期:2024-07-29 修回日期:2024-08-16 出版日期:2024-09-20 发布日期:2024-09-18
通讯作者: †
作者简介:潘建章，副研究员。浙江大学杭州国际科创中心分子智造平台总架构师。中国微米纳米技术学会微纳流控分会秘书长。主要从事微流控光学高灵敏检测、毛细管电泳、临床分析、器官芯片/类器官研究。主持和参与国家自然科学基金、国家科技支撑计划等项目10余项。获教育部科技进步奖一等奖1项。发表论文40余篇，授权发明专利10余件。电子信箱：kelvonpan@zju.edu.cn。
方群，浙江大学求是特聘教授，博士研究生导师。浙江大学化学系微分析系统研究所所长，浙江大学杭州国际科创中心分子智造研究所所长。中国微米纳米技术学会常务理事、微纳流控分会理事长。国家杰出青年科学基金获得者。主要从事微流控分析研究，在超微量高通量微流控分析及筛选、单细胞多组学分析、人工智能+化学、临床分析和现场分析等方向取得了一系列高水平成果。主持国家自然科学基金、国家重点研发计划、“973”计划和“863”计划等项目20余项。发表论文140余篇，授权发明专利31件。电子信箱：Fangqun@zju.edu.cn。
基金资助:
浙江省重点研发计划“领雁”项目(2024C03144);杭州市农业与社会发展研究重点项目(20231203A08)

Application and Development Trend of Microfluidic Technologies in Organoids-based Drug Screening

PAN Jianzhang¹^,²(), ZHENG Xinyu¹, FANG Qun¹^,²^,^†()

1. Institute of Microanalytical Systems, Department of Chemistry, Zhejiang University, Hangzhou 310058, China
2. ZJU-Hangzhou Global Scientific and Technological Innovation Center, Hangzhou 311200, China

Received:2024-07-29 Revised:2024-08-16 Online:2024-09-20 Published:2024-09-18
Contact: †

摘要/Abstract

摘要：

类器官是由干细胞发育来的体外自组织的三维细胞复合体，是比常规二维细胞更具模拟体内生理状态的理想药物筛选模型。微流控技术因其对微量流体的灵活操控能力，很好地契合了类器官高通量药物筛选的技术需求，因此微流控技术在类器官药物筛选中获得了广泛关注和研究。文章对现有基于微流控的类器官培养和药物递送技术等进行了分类综述，在此基础上对微流控类器官技术在患者来源类器官的药物敏感性测试和新药筛选方面的应用进行了介绍，并对微流控在类器官药物筛选更进一步的应用和发展方向进行讨论和展望。

关键词: 类器官, 微流控, 高通量, 药物筛选

Abstract:

Organoids are self-organized three-dimensional cell complexes in vitro developed from stem cells. They serve as ideal drug screening models that more accurately mimic in vivo physiological states compared to conventional two-dimensional cells. Microfluidic technologies, due to their capability for flexible manipulation of micro fluid volumes, perfectly align with the technical requirements for high-throughput drug screening using organoids. Consequently, microfluidic technologies have garnered widespread attention and research in the context of organoids-based drug screening. This paper provided a categorized review of the existing microfluidic technologies for organoid culture and drug delivery, etc. Additionally, it introduced current applications of microfluidic technologies in drug sensitivity testing based on patient-derived organoids and new drug screening. Finally, the paper discussed and forecasted further applications and development directions of microfluidic technologies in organoids-based drug screening.

Key words: organoids, microfluidic, high-throughput, drug screening

潘建章, 郑欣雨, 方群. 微流控技术在类器官药物筛选中的应用与发展趋势[J]. 前瞻科技, 2024, 3(3): 87-96.

PAN Jianzhang, ZHENG Xinyu, FANG Qun. Application and Development Trend of Microfluidic Technologies in Organoids-based Drug Screening[J]. Science and Technology Foresight, 2024, 3(3): 87-96.

参考文献 41

[1]	Zhao Z X, Chen X Y, Dowbaj A M, et al. Organoids[J]. Nature Review. Methods Primers, 2022, 2, doi: 10.1038/s43586-022-00174-y.
[2]	Gjorevski N, Nikolaev M, Brown T E, et al. Tissue geometry drives deterministic organoid patterning[J]. Science, 2022, 375(6576), doi: 10.1126/science.aaw9021.
[3]	Fang G C, Chen Y C, Lu H X, et al. Advances in spheroids and organoids on a chip[J]. Advanced Functional Materials, 2023, 33(19), doi: 10.1002/adfm.202215043.
[4]	Sato T, Vries R G, Snippert H J, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche[J]. Nature, 2009, 459(7244): 262-265.
[5]	Huh D, Hamilton G A, Ingber D E. From 3D cell culture to organs-on-chips[J]. Trends in Cell Biology, 2011, 21(12): 745-754. DOI PMID
[6]	Zhang B Y, Korolj A, Lai B F L, et al. Advances in organ-on-a-chip engineering[J]. Nature Reviews Materials, 2018, 3: 257-278.
[7]	Low L A, Mummery C, Berridge B R, et al. Organs-on-chips: Into the next decade[J]. Nature Reviews Drug Discovery, 2021, 20(5): 345-361.
[8]	Fang G C, Lu H X, Rodriguez de la Fuente L, et al. Mammary tumor organoid culture in non-adhesive alginate for luminal mechanics and high-throughput drug screening[J]. Advanced Science, 2021, 8(21), doi: 10.1002/advs.202102418.
[9]	Wang Y H, Liu M Q, Zhang Y, et al. Recent methods of droplet microfluidics and their applications in spheroids and organoids[J]. Lab on a Chip, 2023, 23(5): 1080-1096. DOI PMID
[10]	Zhang W J, Li D H, Jiang S W, et al. Microfluidic droplets as structural templates for Matrigel to enable 1-week large organoid modeling[J]. Chemical Engineering Science, 2021, 238, doi: 10.1016/j.ces.2021.116632.
[11]	Lu Y C, Fu D J, An D, et al. Scalable production and cryostorage of organoids using core-shell decoupled hydrogel capsules[J]. Advanced Biosystems, 2017, 1(12), doi: 10.1002/adbi.201700165.
[12]	Agarwal T, Banerjee D, Konwarh R, et al. Recent advances in bioprinting technologies for engineering hepatic tissue[J]. Materials Science & Engineering C, Materials for Biological Applications, 2021, 123, doi: 10.1016/j.msec.2021.112013.
[13]	Matai I, Kaur G, Seyedsalehi A, et al. Progress in 3D bioprinting technology for tissue/organ regenerative engineering[J]. Biomaterials, 2020, 226, doi: 10.1016/j.biomaterials.2019.119536.
[14]	Jian H L, Wang M Y, Wang S T, et al. 3D bioprinting for cell culture and tissue fabrication[J]. Bio-Design and Manufacturing, 2018, 1(1): 45-61.
[15]	Jiang S W, Zhao H R, Zhang W J, et al. An automated organoid platform with inter-organoid homogeneity and inter-patient heterogeneity[J]. Cell Reports Medicine, 2020, 1(9), doi: 10.1016/j.xcrm.2020.100161.
[16]	Choo N, Ramm S, Luu J, et al. High-throughput imaging assay for drug screening of 3D prostate cancer organoids[J]. SLAS Discovery, 2021, 26(9): 1107-1124.
[17]	Wiedenmann S, Breunig M, Merkle J, et al. Single-cell-resolved differentiation of human induced pluripotent stem cells into pancreatic duct-like organoids on a microwell chip[J]. Nature Biomedical Engineering, 2021, 5(8): 897-913. DOI PMID
[18]	Fang G C, Lu H X, Al-Nakashli R, et al. Enabling peristalsis of human colon tumor organoids on microfluidic chips[J]. Biofabrication, 2022, 14(1), doi: 10.1088/1758-5090/ac2ef9.
[19]	Schuster B, Junkin M, Kashaf S S, et al. Automated microfluidic platform for dynamic and combinatorial drug screening of tumor organoids[J]. Nature Communications, 2020, 11(1), doi: 10.1038/s41467-020-19058-4.
[20]	Rajasekar S, Lin D S Y, Abdul L, et al. IFlowPlate-a customized 384-well plate for the culture of perfusable vascularized colon organoids[J]. Advanced Materials, 2020, 32(46), doi: 10.1002/adma.202002974.
[21]	Zhu Y J, Wang L, Yu H, et al. In situ generation of human brain organoids on a micropillar array[J]. Lab on a Chip, 2017, 17(17): 2941-2950.
[22]	Wang Y Q, Wang H, Deng P W, et al. In situ differentiation and generation of functional liver organoids from human iPSCs in a 3D perfusable chip system[J]. Lab on a Chip, 2018, 18(23): 3606-3616.
[23]	Puls T J, Tan X H, Husain M, et al. Development of a novel 3D tumor-tissue invasion model for high-throughput, high-content phenotypic drug screening[J]. Scientific Reports, 2018, 8(1), doi: 10.1038/s41598-018-31138-6.
[24]	Lee S H, Hu W H, Matulay J T, et al. Tumor evolution and drug response in patient-derived organoid models of bladder cancer[J]. Cell, 2018, 173(2): 515-528. DOI PMID
[25]	Muckom R, Bao X P, Tran E, et al. High-throughput 3D screening for differentiation of hPSC-derived cell therapy candidates[J]. Science Advances, 2020, 6(32), doi: 10.1126/sciadv.aaz1457.
[26]	Song T Y, Zhang H, Luo Z Q, et al. Primary human pancreatic cancer cells cultivation in microfluidic hydrogel microcapsules for drug evaluation[J]. Advanced Science, 2023, 10(12), doi: 10.1002/advs.202206004.
[27]	Hu Y W, Sui X Z, Song F, et al. Lung cancer organoids analyzed on microwell arrays predict drug responses of patients within a week[J]. Nature Communications, 2021, 12, doi: 10.1038/s41467-021-22676-1.
[28]	Cui Y C, Xiao R R, Zhou Y S, et al. Establishment of organoid models based on a nested array chip for fast and reproducible drug testing in colorectal cancer therapy[J]. Bio-Design and Manufacturing, 2022, 5(4): 674-686.
[29]	Zhang K X, Xi J Y, Wang Y D, et al. A microfluidic chip-based automated system for whole-course monitoring the drug responses of organoids[J]. Analytical Chemistry, 2024, 96(24): 10092-10101.
[30]	Ding S L, Hsu C, Wang Z H, et al. Patient-derived micro-organospheres enable clinical precision oncology[J]. Cell Stem Cell, 2022, 29(6): 905-917. DOI PMID
[31]	Zou Z Y, Lin Z, Wu C L, et al. Micro-engineered organoid-on-a-chip based on mesenchymal stromal cells to predict immunotherapy responses of HCC patients[J]. Advanced Science, 2023, 10(27), doi: 10.1002/advs.202302640.
[32]	Wang Y C, Jeon H. 3D cell cultures toward quantitative high-throughput drug screening[J]. Trends in Pharmacological Sciences, 2022, 43(7): 569-581. DOI PMID
[33]	Rawal P, Tripathi D M, Ramakrishna S, et al. Prospects for 3D bioprinting of organoids[J]. Bio-Design and Manufacturing, 2021, 4(3): 627-640.
[34]	Sun D X, Gao W, Hu H X, et al. Why 90% of clinical drug development fails and how to improve it?[J]. Acta Pharmaceutica Sinica B, 2022, 12(7): 3049-3062. DOI PMID
[35]	Czerniecki S M, Cruz N M, Harder J L, et al. High-throughput screening enhances kidney organoid differentiation from human pluripotent stem cells and enables automated multidimensional phenotyping[J]. Cell Stem Cell, 2018, 22(6): 929-940. DOI PMID
[36]	Renner H, Grabos M, Becker K J, et al. A fully automated high-throughput workflow for 3D-based chemical screening in human midbrain organoids[J]. eLife, 2020, 9, doi: 10.7554/eLife52904..
[37]	Tristan C A, Ormanoglu P, Slamecka J, et al. Robotic high-throughput biomanufacturing and functional differentiation of human pluripotent stem cells[J]. Stem Cell Reports, 2021, 16(12): 3076-3092. DOI PMID
[38]	Hou S R, Tiriac H, Sridharan B P, et al. Advanced development of primary pancreatic organoid tumor models for high-throughput phenotypic drug screening[J]. SLAS Discovery, 2018, 23(6): 574-584. DOI PMID
[39]	Skardal A, Aleman J, Forsythe S, et al. Drug compound screening in single and integrated multi-organoid body-on-a-chip systems[J]. Biofabrication, 2020, 12(2), doi: 10.1088/1758-5090/ab6d36.
[40]	Tao T T, Deng P W, Wang Y Q, et al. Microengineered multi-organoid system from hiPSCs to recapitulate human liver-islet axis in normal and type 2 diabetes[J]. Advanced Science, 2022, 9(5), doi: 10.1002/advs.202103495.
[41]	Xiang D X, He A N, Zhou R, et al. Building consensus on the application of organoid-based drug sensitivity testing in cancer precision medicine and drug development[J]. Theranostics, 2024, 14(8): 3300-3316. DOI PMID

微流控技术在类器官药物筛选中的应用与发展趋势

Application and Development Trend of Microfluidic Technologies in Organoids-based Drug Screening

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 1

编辑推荐

Metrics

访问统计

友情链接

联系我们

官方微信公众号